Investment House LLC Sells 41,180 Shares of Zoetis Inc. $ZTS

Investment House LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 45.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,846 shares of the company’s stock after selling 41,180 shares during the quarter. Investment House LLC’s holdings in Zoetis were worth $7,293,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Savvy Advisors Inc. lifted its holdings in Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after buying an additional 1,114 shares during the period. Sound Income Strategies LLC raised its position in shares of Zoetis by 54.3% during the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock worth $67,000 after acquiring an additional 152 shares during the last quarter. Chicago Partners Investment Group LLC raised its position in shares of Zoetis by 67.0% during the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after acquiring an additional 1,961 shares during the last quarter. QRG Capital Management Inc. lifted its stake in shares of Zoetis by 4.9% in the second quarter. QRG Capital Management Inc. now owns 77,741 shares of the company’s stock worth $12,124,000 after acquiring an additional 3,616 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in Zoetis by 10.0% in the second quarter. Nordea Investment Management AB now owns 2,356,166 shares of the company’s stock valued at $368,245,000 after acquiring an additional 214,889 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Several market write-ups argue Zoetis is undervalued after a roughly 24% one-year pullback and present a buying opportunity; these narratives can attract value-focused investors. Is Zoetis (ZTS) Offering An Opportunity After A 24% One-Year Share Price Pullback
• Positive Sentiment: A Seeking Alpha piece makes a case that Zoetis is “Undervalued And Oversold,” reinforcing the narrative that current levels could be attractive to long-term investors. Zoetis: Undervalued And Oversold
• Positive Sentiment: Wall Street Zen upgraded Zoetis to a “Buy,” which can provide short-term support as some investors chase analyst upgrades. Zoetis (NYSE:ZTS) Upgraded by Wall Street Zen to “Buy” Rating
• Neutral Sentiment: A roundup of eight analyst ratings shows mixed views across the street, indicating no clear consensus and contributing to stock volatility. 7ZTS : What 8 Analyst Ratings Have To Say About Zoetis
• Neutral Sentiment: Aggregated analyst consensus remains around a “Hold,” which suggests many pros see limited near-term upside absent clearer catalysts. Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Hold” by Analysts
• Negative Sentiment: Piper Sandler downgraded ZTS from “Overweight” to “Neutral” and cut its price target sharply (from $190 to $135), a material change that likely pressured the stock and investor sentiment. Piper Sandler downgrades Zoetis (ZTS)

Zoetis Stock Down 0.3%

Shares of NYSE ZTS opened at $124.04 on Friday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The firm has a market cap of $54.66 billion, a PE ratio of 20.88, a P/E/G ratio of 2.15 and a beta of 0.97. The company’s fifty day simple moving average is $123.58 and its 200 day simple moving average is $138.29. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is 35.69%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Barclays assumed coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and issued a $135.00 target price (down previously from $190.00) on shares of Zoetis in a report on Thursday. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday. Finally, KeyCorp began coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Five equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.